Characteristics and Long-Term Risk of Breast Angiosarcoma

Friedrich, Ann-Kristin U.; Reisenbichler, Emily; Heller, Danielle R.; LeBlanc, J.; Park, Tristen S; Killelea, Brigid K.; Lannin, Donald R.

doi:10.1245/s10434-021-09689-2

Cited by 19 publications

(9 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Specifically, PAS patients had a 5-year survival of 50%, while the RAAS patients had a 5-year survival of 43%. This is similar to a recent Surveillance Epidemiology and End Results (SEER) study looking at 313 patients with PAS and 591 RAAS patients, which showed 5-and 10-year survival rates of 49% and 38%, respectively, in PAS patients and of 42% and 27%, respectively, in RAAS patients [17].…”

Section: Discussionsupporting

confidence: 89%

Clinical Outcomes for Primary and Radiation-Associated Angiosarcoma of the Breast with Multimodal Treatment: Long-Term Survival Is Achievable

Kronenfeld

Crystal

Ryon

et al. 2021

Cancers

View full text Add to dashboard Cite

Background: The optimal management of primary angiosarcoma (PAS) and radiation-associated angiosarcoma (RAAS) of the breast remains undefined. Available data show persistently poor survival outcomes following treatment with surgery or chemotherapy alone. The objective of this study was to evaluate long-term outcomes in patients treated with multimodality therapy. Methods: Patients diagnosed with stage I–III PAS or RAAS of the breast were identified from our local tumor registry (2010–2020). Patient demographics, tumor characteristics, and treatment were collected. Primary outcomes were local recurrence (LR), distant recurrence (DR), and median overall survival (OS). A secondary outcome was pathologic complete response (pCR) following neoadjuvant chemotherapy (NAC). Mann–Whitney U, chi-squared, or Fisher exact tests were used to analyze data. Kaplan–Meier curves compared OS for PAS and RAAS. Results: Twenty-two patients met inclusion criteria, including 11 (50%) with RAAS and 11 (50%) with PAS. Compared to PAS patients, RAAS patients were older and had more comorbidities. For RAAS patients, median time from radiation to diagnosis was 6 years (IQR: 5–11). RAAS patients were more likely to have a pCR to NAC (40% vs. 20%, p = 0.72). RAAS patients had a higher LR rate (43% vs. 38%, p = 0.83), and PAS patients were more likely to develop a DR (38% vs. 0%, p = 0.07). Median OS was 81 months in PAS patients and 90 months in RAAS patients (p = 1.00). Discussion: Long-term survival can be achieved in patients with PAS and RAAS who undergo multimodality treatment. NAC can result in pCR. The long-term clinical implications of pCR warrant further investigation.

show abstract

Section: Discussionsupporting

confidence: 89%

Clinical Outcomes for Primary and Radiation-Associated Angiosarcoma of the Breast with Multimodal Treatment: Long-Term Survival Is Achievable

Kronenfeld

Crystal

Ryon

et al. 2021

Cancers

View full text Add to dashboard Cite

show abstract

“…We selected patients with primary breast angiosarcoma as much as possible from the cohort. The lack of a clear definition of primary and secondary breast angiosarcoma in the SEER database could introduce a selection bias when grouping according to whether patients were diagnosed based on a previous tumor 11 . To evaluate the survival outcomes more comprehensively, we calculated both OS and DSS.…”

Section: Discussionmentioning

confidence: 99%

“…The lack of a clear definition of primary and secondary breast angiosarcoma in the SEER database could introduce a selection bias when grouping according to whether patients were diagnosed based on a previous tumor. 11 To evaluate the survival outcomes more comprehensively, we calculated both OS and DSS. DSS was accurate in evaluating the survival of patients with primary disease because there was no need to consider the impact of breast cancer on the cause of death.…”

Section: Discussionmentioning

confidence: 99%

Clinicopathological characteristics and survival outcomes in patients with angiosarcoma of breast

Wang

et al. 2023

Cancer Medicine

View full text Add to dashboard Cite

Background: Angiosarcoma of the breast is a rare malignancy. There are little data evaluating the survival and estimating the prognostic factors. The best surgical management and the role of systemic adjuvant therapy remain ill-defined.This study aimed to investigate the clinicopathological features, survival, and prognostic factors of breast angiosarcoma. Methods:The data on patients diagnosed with breast angiosarcoma were extracted from the Surveillance, Epidemiology, and End Results database . Univariate and multivariate Cox regression analyses were used to estimate the influential prognostic factors. The overall survival (OS) and disease-specific survival (DSS) of patients with breast angiosarcoma were evaluated.Results: This study included 656 patients diagnosed with breast angiosarcoma between 1975 and 2016. The 5-year OS rate of all patients was 44.9% (95% CI 40.8-49.0). In both OS and DSS, Kaplan-Meier survival analyses revealed significant differences for both OS and DSS according to age, year at diagnosis, laterality, grade, and stage (all log-rank p < 0.05). Multivariate analysis suggested that lesions of the right breast, poor differentiation, and advanced stage were independent risk factors for OS or DSS (all p < 0.05). Older age was a risk factor in OS, but was protective in DSS. In primary breast angiosarcoma, age, laterality, grade, and stage were independent prognostic factors in OS and DSS (all p < 0.05).Mastectomy was also a risk factor in DSS (p = 0.034). The proportion of patients with grade III and regional disease was larger in the mastectomy group. Conclusion:Angiosarcoma of the breast had a poor prognosis. In our study, age, laterality, histologic grade, and stage were identified as significant prognostic factors. Why patients with angiosarcoma of the right breast had a worse prognosis remains equivocal. Mastectomy was adopted more often by surgeons in this cohort study for patients with advanced primary breast angiosarcoma.

show abstract

“…It can be divided into primary and secondary angiosarcoma. It has a poor prognosis, with a 5-year survival rate of 40% (1). Primary breast angiosarcoma (PBA) is extremely rare (2).…”

Section: Introductionmentioning

confidence: 99%

Primary breast angiosarcoma: A case report

Qian

Chen

et al. 2023

Front. Surg.

View full text Add to dashboard Cite

BackgroundPrimary breast angiosarcoma (PBA) is a rare sarcoma, accounting for only 0.04% of all breast malignancies, with a difficult diagnosis and a poor prognosis. Mastectomy is the standard treatment, and the role of adjuvant treatment (chemotherapy and/or radiotherapy following surgery) remains uncertain with very few studies.Case PresentationWe report the case of a 17-year-old female patient who presented with a right breast lump that had rapidly increased in size and was hemorrhaging. She was diagnosed with breast angiosarcoma by needle biopsy and pathological evaluation. However, the mass showed a quick tendency to bleed during biopsies. After that, we performed angiography and tumor vascular embolization. The patient underwent a mastectomy followed by adjuvant chemotherapy.ConclusionTumor vascular embolization reduced the surgical risk of PBA with hemorrhage complications. Postoperative therapeutic roles still need further exploration and verification.

show abstract

Characteristics and Long-Term Risk of Breast Angiosarcoma

Cited by 19 publications

References 24 publications

Clinical Outcomes for Primary and Radiation-Associated Angiosarcoma of the Breast with Multimodal Treatment: Long-Term Survival Is Achievable

Clinical Outcomes for Primary and Radiation-Associated Angiosarcoma of the Breast with Multimodal Treatment: Long-Term Survival Is Achievable

Clinicopathological characteristics and survival outcomes in patients with angiosarcoma of breast

Primary breast angiosarcoma: A case report

Contact Info

Product

Resources

About